A Phase 3, Multicenter, Randomized, Placebo-Controlled, Doulbe-Blind, Three-Arm Study to Evaluate the Safety and Efficacy of Tifacogin (Recombinant Tissue Factor Pathway Inhibitor) Administration in Subjects With Severe Community-Acquired Pneumonia